ANDA 205643, held by Exela Pharma. Acetylcysteine.
As of Nov 16, 2026, ANDA 205643 (Acetylcysteine), held by Exela Pharma, was first approved by FDA on Nov 1, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 1, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Acetylcysteine20% ยท solution;inhalation, oral | Acetylcysteine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters